We always have something going on at Juno.
Want to keep up with our most recent developments?
Have a read of our latest news, new product launches and business news.
Filter News by:

Juno Pharmaceuticals appointed as Fresenius Kabi’s exclusive distribution partner for IDACIO® (adalimumab)

We are pleased to announce that Fresenius Kabi Australia Pty Limited (Fresenius Kabi) has appointed Juno Pharmaceuticals (Juno) as their exclusive distribution partner for IDACIO® (adalimumab) (rch) 40 mg solution for injection pre-filled pen & pre-filled syringe. Read more

Celltrion Healthcare Australia and Juno Pharmaceuticals Australia Partner on Biosimilars

Celltrion Healthcare Australia (Celltrion) and Juno Pharmaceuticals (Juno) have entered in to a co-marketing partnership, covering the biosimilar products Herzuma (biosimilar trastuzumab), and Truxima (biosimilar rituximab). Read more

Juno Pharmaceuticals and Amgen Australia announce partnership for the marketing and distribution of biologic medicines Neulasta® (Pegfilgrastim) and Ristempa® (Pegfilgrastim) in Australia.

MELBOURNE, AUSTRALIA – Juno Pharmaceuticals is pleased to announce that Amgen Australia have appointed us as their distribution partner for the exclusive marketing and distribution of Amgen’s biologic medicines Neulasta (Pegfilgrastim) and the launch of Ristempa (Pegfilgrastim). Read more

Canadian Biosimilar Approval Process Update

The Canadian Agency for Drugs and Technology in Health (CADTH) are revising the regulatory process for biosimilars. Following a period of consultation, CADTH has streamlined the assessment process for biosimilars, with shorter approval timelines, fewer submission requirements and abbreviated biosimilar dossier templates. Read more

Introduction of Biosimilar Uptake Drivers in Australia

New biosimilar uptake drivers negotiated late last year, including ‘streamlined authority’ prescribing appear to be making a positive impact on uptake. Read more